[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trigger-points-myofascial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trigger-points-myofascial":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100635047","phase-4-prp-vs-prpbetamethasone-vs-betamethasone-injection-for-upper-trapezius-myofascial-pain-100635047",false,"NCT07547605","PRP vs PRP+Betamethasone vs Betamethasone Injection for Upper Trapezius Myofascial Pain","Comparison of Platelet-Rich Plasma, Combined Platelet-Rich Plasma Plus Betamethasone, and Betamethasone Monotherapy Trigger Point Injections in Patients With Upper Trapezius Myofascial Pain Syndrome: A Prospective, Randomized, Assessor-Blind, Controlled Trial","UMAY-RCT","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Presentation to the Orthopedics and Traumatology outpatient clinic with neck and\u002For shoulder pain\n* Diagnosis of upper trapezius myofascial pain syndrome based on Simons and Travell criteria, including:\n* Presence of a taut band\n* Local tenderness\n* Referred pain pattern\n* Local twitch response\n* Presence of a single active trigger point in the upper trapezius muscle\n* Symptom duration ≥ 4 weeks\n* Pain intensity ≥ 4 on the visual analog scale (VAS)\n* Inadequate response to at least 4 weeks of conservative treatment (physical therapy and\u002For oral analgesics)\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of multiple active trigger points\n* Diagnosis of fibromyalgia according to ACR 2010 criteria\n* Cervical radiculopathy or myelopathy\n* Trigger point injection in the same region within the past 3 months\n* Coagulopathy or current anticoagulant or antiplatelet therapy\n* Known allergy or contraindication to corticosteroids, local anesthetics, or PRP components\n* Active infection (systemic or local)\n* Pregnancy or lactation\n* Thrombocytopenia (platelet count \\\u003C 100,000\u002FµL)\n* Malignancy\n* Inability to cooperate or provide informed consent","ALL","18 Years","65 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Brief Summary\n\nMyofascial pain syndrome (MPS) is a common musculoskeletal condition characterized by active trigger points (TrPs), which are hypersensitive, painful nodules within taut bands of skeletal muscle. The upper trapezius muscle is one of the most frequently affected sites. Trigger point injection (TPI) is a widely used minimally invasive treatment for patients who are refractory to conservative management.\n\nCorticosteroids provide rapid anti-inflammatory effects, whereas platelet-rich plasma (PRP) has regenerative properties through growth factors that may support tissue healing. Despite their widespread use, the optimal injectate for TPI remains unclear. Additionally, the potential benefit of combining PRP with corticosteroids has not been adequately studied in upper trapezius MPS.\n\nThis study is a single-center, prospective, randomized, assessor-blinded controlled trial designed to compare the clinical effectiveness of three injection protocols: (1) PRP plus bupivacaine, (2) PRP plus betamethasone plus bupivacaine, and (3) betamethasone plus bupivacaine with saline (volume-matched control). A total of 150 patients with a single active trigger point in the upper trapezius will be included.\n\nThe primary outcome is pain intensity measured by the visual analog scale (VAS) at 3 months. Secondary outcomes include pressure pain threshold (PPT), cervical range of motion (ROM), rescue analgesic use, recurrence rate, and adverse events at 1 week, 4 weeks, 3 months, and 6 months.\n\nAll injections are performed by the same investigator using a palpation-guided technique, and outcome assessments are conducted by a blinded evaluator.",[28,29,30],"Myofascial Pain Dysfunction Syndrome","Trigger Points, Myofascial","Trigger Point in Trapezius Muscle",[32,33,34,35,36,37,38,39],"platelet-rich plasma","PRP","betamethasone","trigger point injection","myofascial pain syndrome","trapezius","randomized controlled trial","pressure pain threshold","RECRUITING","2026-06-14",{"date":43,"type":44},"2026-06-16","ACTUAL",{"date":46,"type":44},"2026-05-15",{"date":48,"type":22},"2027-01",{"name":50,"class":51},"University of Kyrenia","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100568073","phase-2-comparison-between-botox-and-magnesium-sulfate-effect-in-treatment-of-myofascial-pain-trigger-points-within-the-masseter-muscle-100568073","NCT06676475","Comparison Between Botox and Magnesium Sulfate Effect in Treatment of Myofascial Pain Trigger Points Within the Masseter Muscle","Comparison of the Effectiveness of Botulinum Toxin and Magnesium Sulfate Injections in the Treatment of Myofascial Trigger Points in the Masseter Muscle Randomized Controlled Clinical Trial","MPS MTrPs BTA","Inclusion Criteria:\n\n* Patients diagnosed with orofacial pain and trigger points in the masseter muscle unilaterally or bilaterally for at least period 6 months other criteria\n* Definite diagnosis of myofascial pain based on the DC\u002FTMD criteria with a referral\n* Presence of one or more unilateral or bilateral trigger points in the masseter muscle\n* No history of any invasive procedures of the related masseter muscle (Taşkesen, Cezairli, 2023.)\n\nExclusion Criteria:\n\n* Any painful conditions (other than myofascial trigger points) affecting the orofacial region\n* Any systemic diseases that could affect masticatory function (e.g., rheumatoid arthritis and epilepsy\n* Pregnancy and lactation. (Refahee, Mahrous, Shabaan,2022)","16 Years","50 Years",{"count":63,"type":22},60,[65,66],"PHASE2","PHASE3","The goal of this randomized clinical trial is to compare the effectiveness of Botulinum toxin type A, magnesium sulfate and saline injections in treatment of the masseter muscle trigger points, in patients between 16 - 50 years old with myofascial pain with masseter muscle trigger points. The main questions it aims to answer are:\n\n* which treatment has longer effect of pain release with the least possible side effects and recurrence rate?\n* Which treatment has greater impact on improving patient's quality of life? Researchers will compare Botulinum toxin type A, magnesium sulfate to a placebo saline injections in treatment of the masseter muscle trigger points Participants will attend to the clinic 4 times\n* 1st visit will include taking preoperative records and treatment injection\n* 2nd visit will be follow up and taking records after 1 month\n* 3rd visit will be follow up and taking records after 3 months\n* 4th visit will be follow up and taking records after 6 months",[69,29],"Myofacial Pain",[71,72,73,74,75,76,77,78],"myofascial pain","masseter trigger point","MPS","MTrPs","MgSO4 in myofascial trigger points","BTA in myofascial trigger points","Botox in masseter trigger points","magnesium sulfate in masseter trigger points","NOT_YET_RECRUITING","2024-11-08",{"date":82,"type":44},"2024-11-12",{"date":84,"type":22},"2024-12-01",{"date":86,"type":22},"2025-08",{"name":88,"class":51},"Misr University for Science and Technology",1]